Medication info
Piromet Tablet 15/850 mg (Pioglitazone Hydrochloride, Metformin Hydrochloride)

Piromet Tablet 15/850 mg (Pioglitazone Hydrochloride, Metformin Hydrochloride)

Prescription medicationTablet
Ingredient · strength
Metformin Hydrochloride›850mg / 1 tabletPioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
IYON Pharmaceutical Co., Ltd.
Appearance
White to whitish rectangular film-coated tablets
Packaging
30 tablets (10 tablets/PTP*3)
Approval status
Active

MFDS item code 201903191 · Approved 2019.05.16 · Insurance code 658603770

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum dose of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medicine daily, assess the adequacy of the treatment response, and gradually adjust the dose. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at their existing doses of pioglitazone and metformin. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, the maximum dose of this medicine should not be reached in elderly, debilitated, or malnourished patients. This medicine should generally be administered in divided doses with meals, which can reduce gastrointestinal adverse reactions caused by metformin. Sufficient time is needed to assess the adequacy of the treatment response. Ideally, treatment response should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the previous 2 - 3 months. In clinical use of this medicine, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) is recommended to evaluate changes in HbA1C.

Ingredients

Manufacturer
IYON Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to help control blood glucose levels in patients with type 2 diabetes when combined with diet and exercise. Taking pioglitazone and metformin together can effectively improve blood glucose levels. It is a medication to assist patients in managing their blood sugar levels, contributing to maintaining health through consistent treatment.

Dosage and Administration

Adult dosage

For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum dose of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medicine daily, assess the adequacy of the treatment response, and gradually adjust the dose. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at their existing doses of pioglitazone and metformin. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, the maximum dose of this medicine should not be reached in elderly, debilitated, or malnourished patients. This medicine should generally be administered in divided doses with meals, which can reduce gastrointestinal adverse reactions caused by metformin. Sufficient time is needed to assess the adequacy of the treatment response. Ideally, treatment response should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the previous 2 - 3 months. In clinical use of this medicine, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) is recommended to evaluate changes in HbA1C.

Precautions

This medication may cause severe lactic acidosis, so those with impaired kidney function or heart disease should exercise special caution. If sudden symptoms of heart failure, weight gain, shortness of breath, or swelling occur while taking this medication, consult a physician immediately. This medication should not be administered to patients with impaired liver function, and if liver dysfunction is suspected, regular liver function tests should be performed. This medication should not be used in patients with a history of bladder cancer or active bladder cancer. Women who are pregnant or breastfeeding should not take this medication, and premenopausal women should use appropriate contraception to avoid the possibility of pregnancy while on this medication. Elderly patients may have reduced kidney function, so the dosage of this medication should be carefully adjusted, and regular kidney function tests should be performed. Excessive alcohol consumption should be avoided while taking this medication, and temporary discontinuation may be required in cases of dehydration, severe infection, or before and after surgery. Symptoms of hypoglycemia may occur, so caution is advised when skipping meals or engaging in vigorous exercise. This medication can interact with other medications, so if you are taking other drugs, be sure to inform your physician or pharmacist. If any unusual symptoms or discomfort persists or worsens, contact healthcare professionals immediately.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • fatigue
  • myalgia
  • dyspnea
  • asthenia
  • abdominal pain
  • hypothermia
  • hypotension
  • resistance bradyarrhythmia
Show 38 more
  • congestive heart failure
  • excessive and rapid weight changes
  • dyspnea
  • edema
  • upper respiratory tract infection
  • diarrhea
  • complex edema
  • peripheral edema
  • headache
  • nausea
  • urinary tract infection
  • sinusitis
  • dizziness
  • lower limb edema
  • weight gain
  • myalgia
  • dental disorders
  • worsening of diabetes
  • pharyngitis
  • anemia
  • decreased vision
  • diabetic macular edema
  • liver failure
  • edema
  • fluid retention
  • volumetric-related cases
  • fractures
  • dyspepsia
  • insomnia
  • dry mouth
  • constipation
  • abdominal distension
  • gastroesophageal reflux disease
  • gastric and intestinal air retention
  • increased serum creatinine
  • increased blood urea nitrogen
  • abnormal blood glucose levels
  • arthralgia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air and moisture. It is also safe to store the medication at room temperature, between 1 to 30 degrees Celsius, avoiding extremely hot or cold places.

Appearance and packaging

Appearance

White to whitish rectangular film-coated tablets

Package unit

30 tablets (10 tablets/PTP*3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.